Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 21, 2025; 31(47): 114789
Published online Dec 21, 2025. doi: 10.3748/wjg.v31.i47.114789
Published online Dec 21, 2025. doi: 10.3748/wjg.v31.i47.114789
Resistance reversal: Taiwan’s Helicobacter pylori trends defy global norms
Taly Issa, Medical School, University of Nicosia, Nicosia 24005, Cyprus
Pierre Zalloua, Department of Public Health and Epidemiology, Khalifa University, Abu Dhabi 127788, United Arab Emirates
Iyad A Issa, Department of Gastroenterology and Hepatology, Harley Street Medical Center, Abu Dhabi 41475, United Arab Emirates
Author contributions: Issa IA designed the overall concept and outline of the manuscript; Issa T and Zalloua P contributed to the discussion and design of the manuscript; Issa IA, Zalloua P and Issa T contributed to the writing, and editing the manuscript, illustrations, and review of literature; all authors have read and approved the final manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Iyad A Issa, MD, Doctor, Department of Gastroenterology and Hepa
Received: September 28, 2025
Revised: October 5, 2025
Accepted: October 31, 2025
Published online: December 21, 2025
Processing time: 82 Days and 16.7 Hours
Revised: October 5, 2025
Accepted: October 31, 2025
Published online: December 21, 2025
Processing time: 82 Days and 16.7 Hours
Core Tip
Core Tip: This multicenter Taiwanese study reveals a sharp rise in Helicobacter pylori tetracycline resistance once negligible, now clinically relevant threatening the efficacy of bismuth-based quadruple therapy. As dual resistance emerges and empiric regimens falter, potassium-competitive acid blockers (PCABs) offer a potent pharmacologic pivot. Integrating PCABs and resistance-guided strategies may be key to sustaining eradication success in the face of evolving antimicrobial threats.